This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mazooz, G. Articles by Neeman, M. Search for Related Content PubMed PubMed Citation Articles by Mazooz, G. Articles by Neeman, M.

Development of Magnetic Resonance Imaging Contrast Material for In vivo Mapping of Tissue Transglutaminase Activity

¹ Departments of Biological Regulation and ² Biological Services, The Weizmann Institute of Science, Rehovot 76100, Israel; Departments of ³ Medicine and ⁴ Radiology Oncology, Duke University Medical Center, Durham, North Carolina

Requests for reprints: Michal Neeman, Department of Biological Regulation, The Weizmann Institute of Science, Rehovot 76100, Israel. Phone: 9728-934-2487; Fax: 9728-934-2487; E-mail: michal.neeman{at}weizmann.ac.il.

Transglutaminases are a family of enzymes that play an important role in tissue remodeling by catalyzing covalent cross-links between proteins of the extracellular matrix. Elevated activity of transglutaminase was shown at the boundaries of invading tumors, in association with angiogenesis, in stabilization of atherosclerotic plaques, and in generation of blood clots. The aim of this work was to develop a low molecular weight substrate of transglutaminase that could serve for noninvasive magnetic resonance and optical mapping of transglutaminase-mediated cross-linking activity. A 2 kDa contrast material was generated which showed cross-linking by either tissue transglutaminase or factor XIII in the context of multicellular tumor spheroids or fibrin clots, respectively. Successful detection by nuclear magnetic resonance microscopy of transglutaminase-mediated cross-linking of the contrast material to MCF7 multicellular spheroids provides hope that this approach could potentially be developed for clinical demarcation of sites of transglutaminase activity.

This article has been cited by other articles:

				M.-F. Penet, K. Glunde, M. A. Jacobs, A. P. Pathak, and Z. M. Bhujwalla Molecular and Functional MRI of the Tumor Microenvironment J. Nucl. Med., May 1, 2008; 49(5): 687 - 690. [Full Text] [PDF]

				Z. M Bhujwalla Molecular Imaging of the Tumor Microenvironment Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 519 - 522. [Abstract] [Full Text] [PDF]